WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong
· Delayed Price · Currency is HKD 41.15
-1.70 (-3.97%)
Apr 3, 2025, 4:08 PM HKT
WuXi XDC Cayman Revenue
In the year 2024, WuXi XDC Cayman had annual revenue of 4.05B CNY with 90.80% growth. WuXi XDC Cayman had revenue of 2.39B in the half year ending December 31, 2024, with 261.14% growth.
Revenue
4.05B CNY
Revenue Growth
+90.80%
P/S Ratio
11.44
Revenue / Employee
1.99M CNY
Employees
2,041
Market Cap
49.38B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.05B | 1.93B | 90.80% |
| Dec 31, 2023 | 2.12B | 1.13B | 114.44% |
| Dec 31, 2022 | 990.42M | 679.29M | 218.33% |
| Dec 31, 2021 | 311.13M | 214.78M | 222.91% |
| Dec 31, 2020 | 96.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |